Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ultrasound sharpen the surgical map for ovarian cancer near the liver?

NCT ID NCT07808320

Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study tests whether a standardized ultrasound approach can reliably classify how ovarian cancer involves the liver area before surgery. Researchers will compare ultrasound images with what surgeons actually find during operations, using tissue samples as an extra check when available. The goal is to develop a clear, repeatable ultrasound protocol that helps surgeons plan cytoreductive surgery for advanced or recurrent ovarian cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Standardized two-dimensional ultrasound imaging protocol
What this could lead to
If successful, this could give surgeons a reliable, non-invasive way to plan operations for ovarian cancer that has spread near the liver, potentially improving surgical outcomes.
What could go wrong
This is a small pilot study with only 20 participants, so results may not apply broadly. Ultrasound may not always clearly distinguish between types of liver involvement, and the approach needs validation in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women aged 18 years or older with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma undergoing complete cytoreductive surgery, with or without suspected liver-area involvement. The study includes both a retrospective cohort of patients treated from March 2026 until Ethics Committee approval and a prospective cohort enrolled after study approval.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged ≥18 years. * Suspicious or histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. * Suspicious primary FIGO stage III-IV disease or recurrent ovarian cancer undergoing complete cytoreductive surgery. * For participants included in the prospective cohort, written informed consent for study participation and processing of personal data. * For the retrospective cohort, eligible participants may include individuals for whom informed consent cannot be obtained because they are deceased or cannot be contacted despite all reasonable efforts to trace them. Data processing will be conducted in accordance with applicable Italian data protection regulations. Exclusion Criteria: \- Previous radiotherapy involving the hepatic area

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer Recurrent ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.